AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-106002617/after-close-point.html" title="Facts and information about AFTER THE CLOSE.(TO THE POINT)">AFTER THE CLOSE.(TO THE POINT)</a>
Close
Set up an RSS feed that alerts you when new articles from Investor's Business Daily are available.
Frequently asked questions about RSS feeds
AFTER THE CLOSE.(TO THE POINT)
QWEST said SEC staff will seek action for excluding profit data related to its US West buy in a Jan. '01 release. Also, Qwest may take a $20 bil-$30 bil loss under accounting rule FAS 142.
CONTINENTAL AIRLINES said it'll be hard to end losses in Q2. Analysts see a Q2 gain after a Q1 loss.
BRISTOL-MYERS will pay $32 ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- Dr Reddy's sells Goa unit to Watson Pharma.
- News wire article from: PTI - The Press Trust of India Ltd. December 16, 2005 700+ words
Dr Reddy's sells Goa unit to Watson Pharma New Delhi, Dec 16 (PTI) Hyderabad-based pharma major...undisclosed sum. "We have signed an agreement to this effect with Watson Pharma sometime back," a company spokesperson told PTI from Hyderabad...
- Wishbone/ITP has been chosen as agency of record for Watson Pharma's Androderm...
- Magazine article from: Medical Marketing & Media April 1, 2004 700+ words
Wishbone/ITP has been chosen as agency of record for Watson Pharma's Androderm testosterone replacement patch as well as MedPointe Pharmaceuticals' Zomig, which is indicated for the acute treatment of migraines.
- Publication No. WO/2009/087674 Published on July 16, Assigned to WATSON PHARMA...
- News wire article from: US Fed News Service, Including US State News July 18, 2009 700+ words
...Narayan Bhanu, all from India, have developed a process for resolving racemic pregabalin. The patent has been assigned to WATSON PHARMA PVT. LTD., Maharashtra, India. According to an abstract posted by the World Intellectual Property Organization, the...
- Publication No. WO/2009/087672 Published on July 16, Assigned to WATSON PHARMA...
- News wire article from: US Fed News Service, Including US State News July 18, 2009 700+ words
...from India, have developed a process for preparing stable amorphous racemic lansoprazole. The patent has been assigned to WATSON PHARMA PVT. LTD., Maharashtra, India. According to an abstract posted by the World Intellectual Property Organization, the...
- Publication No. WO/2009/087673 Published on July 16, Assigned to WATSON PHARMA...
- News wire article from: US Fed News Service, Including US State News July 18, 2009 700+ words
...India, have developed a process for preparation of Anagrelide Hydrochloride Monohydrate. The patent has been assigned to WATSON PHARMA PVT. LTD., Maharashtra, India. According to an abstract posted by the World Intellectual Property Organization, the...
- Watson Pharma gets FDA OK for Goa prod.
- Newspaper article from: Pharma Marketletter September 24, 2007 700+ words
Generics and specialty drugmaker Watson Pharmaceuticals has received its first US Food and Drug Administration product approval at its Goa, India, facility, and says it plans to request the agency's clearance of further solid dosage form products. The US drugmaker said that, by early 2008, the Goa
- Watson Pharma bid $1.9B for Andrx.(Watson Pharmaceuticals Inc.)
- Newspaper article from: Pharma Marketletter March 20, 2006 700+ words
Watson Pharmaceuticals says it has reached a definitive merger agreement to acquire all outstanding shares of common stock of fellow US firm Andrx Corp in an all-cash transaction for $25.00 per share, or a total price of approximately $1.9 billion. Andrx, whose capabilities complement those of
- Watson Pharma to divest injectables facility.(Watson Pharmaceuticals...
- Newspaper article from: Pharma Marketletter April 3, 2006 700+ words
US specialty drugs firm Watson Pharmaceuticals says that, as part of an ongoing effort to optimize its manufacturing operations, it plans to divest its injectable manufacturing facility located in Phoenix, Arizona. This unit currently makes 15 products, including several for third parties. Watson